Objective To understand nutritional and inflammatory factors contributing to serum glutamine levels and their relationship to hospital-acquired infections (HAIs) after aneurysmal subarachnoid hemorrhage (SAH).
Malnutrition has been associated with impaired immunologic function leading to increased rates of infection. 1 An assessment of nutritional profiles measured by indirect calorimetry found that patients with subarachnoid hemorrhage (SAH) had average resting energy expenditure rates between 40% and 75% above baseline levels. 2, 3 We have described an independent relationship between inflammation and negative nitrogen balance that was predictive of hospital-acquired infection (HAI) and long-term recovery after SAH. 4 As a further exploration of the relationship between protein catabolism and secondary injury after SAH, we hypothesized that glutamine levels may have a significant role in identifying patients at risk of developing secondary complications with a rapid decline correlated to the development of HAIs after SAH.
In non-SAH populations, a net negative energy balance has been shown to result in protein catabolism and depletion of amino acids necessary for cellular repair and host defenses. Clinically this has been manifest by low levels of amino acids such as glutamine. 5 None of the previous studies have investigated the relationships among serum glutamine levels, metabolic state, and outcome after SAH, where the stress responses after SAH are similar to that observed in medical illnesses such as acute respiratory distress syndrome and sepsis. 2 We investigated this relationship by analyzing levels of serum glutamine and tumor necrosis factor α receptor 1a (TNFαR1a) and time to HAI in a subset of patients previously enrolled in a prospective observational cohort study of the sequelae of the immune-mediated malnutrition after SAH.
Methods

Patient selection and data collection
This is a retrospective analysis of a subset of consecutively enrolled patients in a prospective observational study that had available serum from all 4 predefined phases during the study period 4 and serum collected for amino acid and inflammatory marker analysis. Clinical care for patients with SAH has been described previously 6 and conformed to established guidelines. 7, 8 All underwent serial assessments of inflammatory and metabolic parameters during the first 14 days after SAH in a systematic manner as previously reported. 4 Inflammatory and metabolic parameters were measured during the same 24 hours within each period. Data collection was considered complete in instances when patients died or were discharged from the hospital prior to completion of the study period. The SAH data collection materials and practices used in the ongoing SAH outcomes project have been previously described. 4 All were tested at 3 months for functional disability. Each patient was screened daily for the development of infectious complications, using established criteria for HAIs. 9 We recorded the calendar date for each infectious complication, which allowed for the quantification of the true incidence of HAIs as those infections that developed ≥72 hours after ictus and for time-to-event analysis. 10 
Biomarker measurements
Quantitation of glutamine Glutamine was measured in plasma samples using ultraperformance liquid chromatography-tandem mass spectrometry. Glutamine was assayed in the plasma samples by mixing 10 μL of plasma and 10 μL of internal standard with 1 mL of TDFHA (tridecafluoroheptanoic acid) in an LCMS (liquid chromatography-mass spectrometry) vial. After vortexing for 5 minutes, the vial was placed in an autosampler at 4°C.
Liquid chromatography-tandem mass spectrometry analysis was performed on a platform comprising a triple quadrupole Waters Xevo TQ-S (Waters, Milford, MA) equipped with an electrospray ionization source and integrated with a Waters Acquity UHPLC (ultra-high performance liquid chromatography) controlled by MassLynx software 4.1. Chromatographic separation was performed by injecting 5 μL of the sample onto a Waters C18 BEH column (2.1 × 100 mm, 1.7 μm, 130Å) equipped with a Vanguard BEHC18 precolumn and maintained at 35°C. The flow rate was maintained at 650 μL/min. The initial flow conditions were 99.5% solvent A (water containing 0.5 mm TDFHA) and 0.5% solvent B (0.5 mm TDFHA in acetonitrile). Solvent B was raised to 30% over 14 minutes and lowered back to 0.5% by 17.5 minutes and remained at initial conditions for a total run time of 31.5 minutes. The retention time for glutamine was 2.02 minutes. The mass spectrometer was operated under multiple reaction monitoring mode with positive electrospray ionization with the following parameters: capillary voltage: 1.5 kV; cone gas flow: 300 L/h; desolvation gas: 1,200 L/h; and gas temperature: 600°C. The multiple reaction monitoring transition 146.9 > 83.9 was utilized for quantitation with cone voltage 25 and collision energy 16. Peak integration and data analysis were performed with TargetLynx 4.1 (Waters). Intraand interassay precision was <10%.
Quantitation of TNFαR1a
TNFαR1a was measured in plasma by Quantikine Human sTNFR1a immunoassay (R&D Systems, Minneapolis, MN).
Glossary CI = confidence interval; HAI = hospital-acquired infection; IQR = interquartile range; SAH = subarachnoid hemorrhage; TDFHA = tridecafluoroheptanoic acid; TICS = Telephone Interview for Cognitive Status; TNFαR1a = tumor necrosis factor α receptor 1a.
Intra-and interassay precision was <5.0% and <8.8%, respectively. Normal range is 484-1,407 pg/mL.
Outcome assessments
Outcome was assessed prospectively 3 months posthemorrhage with a 7-point version of the modified Rankin Scale rated from death to symptom-free full recovery 11 and the Telephone Interview for Cognitive Status (TICS). 12 All clinical and outcome endpoints were classified according to a priori criteria and adjudicated at a weekly research meeting, as previously described. 4 Statistical analysis Given this was a retrospective analysis, we did not perform a sample size calculation a priori. The sample size was based on the last 77 consecutive subjects enrolled in the previous cohort study. Continuous variables were assessed for normality and reported using accepted standards for parametric and nonparametric data. Categorical variables were reported as count and proportions in each group. Low 14-day mean serum glutamine levels were defined as values below the 14-day mean glutamine level. Multivariable linear regression analyses were performed to determine factors associated with serum glutamine levels by entering in those factors found to have a p value ≤0.1 on univariate analysis. The occurrence of the first HAI was treated as a censored event by postbleed day and corresponding study period. Baseline characteristics that were found on univariate analysis to be associated (p ≤ 0.1) with HAI were entered into a Cox proportional hazards model to calculate hazard ratios and corresponding 95% confidence interval (CI) for developing HAI. Tests for interaction were performed and reported when found to be significant. For all tests, significance was set at p < 0.05. All analyses were performed with SPSS version 24.0 (IBM Corp., Armonk, NY). Standard protocol approvals, registrations, and patient consents Consent and conduct of this study were approved by the institutional review board and consistent with guiding principles for research involving humans. 13 
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Results
Patient characteristics
There were 77 patients that underwent serum glutamine and TNFαR1a analysis, with a mean age of 55 ± 15 years, 66% women, a median admission Hunt and Hess grade of 2, and modified Fisher score of 3. During the first 14 days after hemorrhage, 18 patients (23%) developed an HAI. Baseline comparisons of patients by HAI status are shown in table 1. Pneumonia was the most common infection, occurring in 15 patients (19%), followed by urinary tract infections (n = 11, 15%), meningitis (n = 6, 8%), and blood stream infections (n = 2, 3%).
Factors associated with serum glutamine levels
The mean serum TNFαR1a level during the study period was 1,228.25 ± 606.6 pg/mL and glutamine 219.4 ± 94 μg/mL. There was a progressive decline in the serum glutamine levels over the 14-day study period (analysis of variance F test, p < 0.001) In a multivariate linear regression model adjusting for admission Hunt and Hess grade, modified Fisher score, and caloric intake, serum glutamine levels were found to be associated with a net negative nitrogen balance (β: 5.023; 95% CI: 0.806-9.241, p = 0.02) and TNFαR1a levels (β: −0.036; 95% CI: −0.07 to −0.002, p = 0.04).
Outcome assessments HAI developed on postbleed day 8 ± 3. Patients developing HAI had lower serum glutamine levels (232 ± 83 vs 163 ± 112 μg/mL, p = 0.01) and higher TNFαR1a levels (1,503 ± 543 vs 1,138 ± 611 pg/mL, p = 0.03). A graphical representation of serum glutamine and TNFαR1a levels over the study period by HAI status is shown in figure 1 . In a univariate model, a low mean serum glutamine level (<219 μg/mL) was associated with time to development of an HAI by postbleed day 14 (figure 2). Low 14-day mean serum glutamine level as well as admission Hunt and Hess grade were associated with time to development of HAI after correcting for caloric intake, age, mechanical ventilation, and body mass index ( 
Discussion
We found that rapidly declining serum glutamine that was linked to net negative nitrogen balance and inflammation was e424 Neurology | Volume 91, Number 5 | July 31, 2018 Neurology.org/N associated with a significantly shorter time to development of HAI within the first 14 days after SAH. Furthermore, on univariate analysis, low 14-day mean serum glutamine levels were associated with poor cognitive and functional recovery 3 months after injury.
Similar findings with protein energy catabolism leading to glutamine depletion and HAIs have been identified in non-SAH populations. 5 Glutamine serves as a vital cell-signaling molecule in states of illness and injury 14 and regulate the expression of many genes related to metabolism, signal transduction, cell defense, and repair, and to activate intracellular signaling pathways. 15 The release of glutamine from muscle and other sources after stress, illness, and injury serves as a "stress signal," which results in activation of genes vital to cellular protection and immune regulation. 16 The presence of adequate circulating glutamine is likely an important factor in preserving cellular energetics, preservation of muscle mass, and supporting immune function during critical illness.
This study has limitations worth noting. The patients in this retrospective analysis are a subset of a previous prospective study, and as a result, our conclusions are limited by the post hoc analysis. As such, we cannot eliminate the possibility that TNFαR1a rose in response to infection, and although our analyses do indicate a strong relationship between glutamine and TNFαR1a, we cannot prove causality in this pilot study. However, the rates of infection are similar to our larger cohort study, and by selecting consecutive patients without regard to their outcomes, we believe any selection bias was minimized. In addition, our results may be inadequately powered, although they do provide preliminary evidence for a link between declining serum glutamine levels and infectious complications after SAH. Finally, as we previously noted, 4 our outcome measures of TICS and modified Rankin Scale may not be appropriate measures of recovery related to malnutrition. Preserved motor strength, physical recovery, and fatigue are likely better markers of the true influence of immune-mediated malnutrition on outcome after critical illness. 17 A composite view of our results from this and previous studies indicates that malnutrition, related to hypermetabolism, underfeeding, and inflammation-mediated protein catabolism is prevalent after SAH and associated with short-term secondary injury and long-term poor outcome. 4, [18] [19] [20] Aspects related to undernutrition may be modifiable, but recent studies indicate that the overall amount of caloric delivery may not be as important as specific substrate delivery. 21, 22 Protein energy malnutrition may be a suitable target for intervention with amino acid supplementation focusing on a reduction of infectious complications and improving recovery. Alternatively, the decrement in glutamine may represent epiphenomenon of inflammatory disease and may only signal risk.
One aspect of malnutrition-related injury and recovery not addressed by current studies involves the influence of acute muscle wasting on physical recovery and fatigue after SAH. Muscle wasting is directly linked to a catabolic state, and recent intervention studies have demonstrated an ability to reduce muscle wasting with a targeted nutritional supplementation and exercise regimen. 23 A dual-therapy approach may be a reasonable next step to better understand the implications of malnutrition and methods by which to optimize physical recovery after SAH.
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